Manufacturer of Controlled Substances; Notice of Registration, 4833 [2012-1981]
Download as PDF
Federal Register / Vol. 77, No. 20 / Tuesday, January 31, 2012 / Notices
Schedule
Drug
wreier-aviles on DSK5TPTVN1PROD with NOTICES
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
5-Methoxy-N-Ndimethyltryptamine (7431).
Alpha-methyltryptamine (7432) ....
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
5-Methoxy-N,Ndiisopropyltryptamine (7439).
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
Federal Bureau of Investigation
I
Manufacturer of Controlled
Substances; Notice of Registration
[OMB Number 1110–0004]
I
By Notice dated June 7, 2011, and
published in the Federal Register on
June 16, 2011, 76 FR 35243, Archimica,
Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
I
I
I
I
I
Drug
I
I
I
I
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
II
II
II
I
II
II
II
II
II
II
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol. In reference to
drug code 7370
(Tetrahydrocannabinols), the company
will manufacture a synthetic THC. No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cayman Chemical Company to
manufacture the listed basic classed of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cayman Chemical
Company to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its customers
for Amphetamine (1100).
The company plans to acquire the
listed controlled substances in bulk
from a domestic source in order to
manufacture other controlled substances
in bulk for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Archimica, Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Archimica, Inc., to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: January 23, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: January 23, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–1977 Filed 1–30–12; 8:45 am]
[FR Doc. 2012–1981 Filed 1–30–12; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Mar<15>2010
15:20 Jan 30, 2012
4833
Jkt 226001
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Agency Information Collection
Activities; Proposed Collection,
Comments Requested: Extension of a
Currently Approved Collection;
Number of Full-Time Law Enforcement
Employees as of October 31
30-day Notice of Information
Collection Under Review.
ACTION:
The Department of Justice, Federal
Bureau of Investigation, Criminal Justice
Information Services Division (CJIS)
will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and clearance in
accordance with established review
procedures of the Paperwork Reduction
Act of 1995. The proposed information
collection is published to obtain
comments from the public and affected
agencies. This proposed information
collection was previously published in
the Federal Register Volume 76,
Number 228, page 72977, on November
28, 2011, allowing for a 60 day comment
period.
The purpose of this notice is to allow
for an additional 30 days for public
comment until March 1, 2012. This
process is conducted in accordance with
5 CFR 1320.10.
Written comments and/or suggestions
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to Mr. Gregory E.
Scarbro, Unit Chief, Federal Bureau of
Investigation, CJIS Division, Module E–
3, 1000 Custer Hollow Road, Clarksburg,
West Virginia 26306; facsimile (304)
625–3566.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Comments
should address one or more of the
following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 77, Number 20 (Tuesday, January 31, 2012)]
[Notices]
[Page 4833]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-1981]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated June 7, 2011, and published in the Federal Register
on June 16, 2011, 76 FR 35243, Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807-1229, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Phenylacetone (8501)....................... II
Methadone Intermediate (9254).............. II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution and sale to its customers for Amphetamine
(1100).
The company plans to acquire the listed controlled substances in
bulk from a domestic source in order to manufacture other controlled
substances in bulk for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Archimica, Inc., to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Archimica, Inc., to ensure that the company's registration
is consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: January 23, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-1981 Filed 1-30-12; 8:45 am]
BILLING CODE 4410-09-P